On May 7, 2020, Catalent announced Phase 3 study for lenzilumab, the companyﾒs proprietary Humaneeredﾮ anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. From its Philadelphia facility, Catalent provided clinical supply support to Humanigen and its partners to accelerate the instigation of this clinical trial.